News Shionogi puts up to $600m behind BioVersys antibiotics Shionogi has added to its antibiotics pipeline by taking an option on a preclinical-stage candidate from BioVersys for non-tuberculous mycobacteria.
News AMR biotech BioVersys plans to float on Swiss stock exchange BioVersys has filed to list on the Swiss Stock Exchange, hoping to raise CHF80m for its novel antibacterial candidates.
News GSK commits to further support of BioVersys’ TB drug GSK has expanded a collaboration with BioVersys on a new drug candidate for tuberculosis (TB) and contributed to an extension to the Swiss biotech’s third-round financing.
News Taiho's late-stage Duchenne candidate fails trial Taiho has suffered a blow to its near-term pipeline after a drug candidate for Duchenne muscular dystrophy (DMD) missed the mark in a phase 3 trial.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face